middle.news
Racura Oncology Advances MYC-Targeting Drug Amid $11.1M Loss
5:21pm on Tuesday 25th of August, 2026 AEST
•
Healthcare
Read Story
Racura Oncology Advances MYC-Targeting Drug Amid $11.1M Loss
5:21pm on Tuesday 25th of August, 2026 AEST
Key Points
Loss after tax surges to $11.09 million
Revenue declines 22.2% to $613,291
Discovery of (E,E)-bisantrene as potent MYC gene silencer
Three clinical trials underway in AML, lung cancer, and cardioprotection
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Racura Oncology (ASX:RAC)
OPEN ARTICLE